Try our mobile app

Switch to company model in classical logic    *

General information

Country: CHINA

Sector: Pharmaceutical Retailers

Categories: @china   

111, Inc. operates as a digital and mobile healthcare platform. The Company offers pharmacy distribution, medical consultancy, e-prescription, and other services. 111 serves patients in China.
Website: yaoex.com



Growth: Bad revenue growth rate -88.5%, there is slowdown compared to average historical growth rates -5.1%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +14.8%

Profitability: LTM EBITDA margin is positive, +1.7%. Gross margin is low, +5.9%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 32.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 807.2% higher than minimum and 64.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -0.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: YI
Share price, USD:  (-2.0%)3.86
year average price 4.68  


year start price 6.57 2025-08-14

max close price 7.34 2025-08-20

min close price 2.56 2025-12-31

current price 3.86 2026-08-13
Common stocks: 85 969 268

Dividend Yield:  0.0%
FCF Yield LTM: 32.8%
EV / LTM EBITDA: 11.3x
EV / Sales: 0.2x
Margin (EBITDA LTM / Revenue): 1.7%
Fundamental value created in LTM:
Market Cap ($m): 332
Net Debt ($m): -37
EV (Enterprise Value): 295
Price to Book: -3.3x
Latest review:

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-17prnewswire.com

111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

2025-09-17prnewswire.com

111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

2025-06-19prnewswire.com

111, Inc. Announces First Quarter 2025 Unaudited Financial Results

2025-03-20seekingalpha.com

111, Inc. (YI) Q4 2024 Earnings Call Transcript

2025-03-20prnewswire.com

111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

2025-02-20prnewswire.com

111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

2025-01-08prnewswire.com

111, Inc. Announces ADS Ratio Change

2024-11-27seekingalpha.com

111, Inc. (YI) Q3 2024 Earnings Call Transcript

2024-11-27prnewswire.com

111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

2024-11-04prnewswire.com

111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol YI YI YI YI YI YI YI YI YI YI YI YI YI YI YI YI
reportedCurrency CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-12-17 2025-09-17 2025-06-20 2024-11-27 2024-08-29 2024-03-21 2023-11-30 2023-06-15 2023-03-23 2022-09-30 2022-06-30
acceptedDate 2025-12-17 06:13:16 2025-09-17 06:09:10 2025-06-20 06:20:04 2025-04-29 06:05:37 2024-11-27 06:02:01 2024-08-29 06:04:08 2024-03-21 06:55:08 2024-05-14 08:49:42 2023-11-30 06:04:34 2023-06-15 06:47:39 2023-03-23 06:03:23 2023-04-28 06:18:03 2022-09-29 20:00:00 2022-06-29 20:00:00 2022-04-29 06:54:19 2021-04-30 06:05:03
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 419M 3 206M 3 529M 14 401M 3 601M 3 424M 3 528M 14 948M 3 665M 3 477M 3 697M 13 517M 3 349M 3 037M 12 426M 8 203M
costOfRevenue 2 823M 3 111M 3 334M 13 572M 3 390M 3 305M 3 320M 14 500M 3 475M 3 270M 3 461M 12 677M 3 147M 2 845M 11 805M 7 837M
grossProfit 25M 95M 195M 829M 211M 120M 209M 448M 191M 208M 236M 840M 202M 192M 621M 366M
grossProfitRatio 0.059 0.03 0.055 0.058 0.035 0.059 0.052 0.06 0.064 0.06 0.063
researchAndDevelopmentExpenses 0 15M 0 0 0 18M 18M 0 25M 25M 0 140M 0 0 189M 92M
generalAndAdministrativeExpenses 16M 17M 18M 71M 14M 17M 19M 224M 46M 39M 169M 747M 176M 160M 752M 447M
sellingAndMarketingExpenses 62M 66M 68M 314M 77M 80M 80M 448M 96M 90M 89M 458M 108M 101M 513M 400M
sellingGeneralAndAdministrativeExpenses 78M 84M 86M 385M 91M 98M 99M 673M 141M 129M 259M 664M 284M 261M 720M 528M
otherExpenses 103M -3M 109M 442M 117M 118 000 -123 000 126M 38 000 1M -578 000 408M -976 000 10M 354M 219M
operatingExpenses 180M 95M 195M 827M 208M 116M 205M 799M 271M 249M 258M 1 211M 283M 272M 1 263M 839M
costAndExpenses 420M 3 206M 3 529M 14 399M 3 598M 3 421M 3 525M 15 298M 3 746M 3 519M 3 718M 13 888M 3 429M 3 117M 13 068M 8 676M
interestIncome 682 000 140 604 1M 7M 2M 2M 2M 9M 2M 2M 2M 8M 3M 1M 10M 6M
interestExpense 7M 7M 9M 28M 8M 7M 8M 20M 5M 5M 4M 13M 4M 3M 5M 9M
depreciationAndAmortization 0 4M 0 17M 2M 2M -4M 22M 2M 4M 5M 41M 4M 0 27M 14M
ebitda 782 262 4M 1M 25M 4M 5M 5M -311M -78M -38M -17M -322M -77M -92M -588M -459M
ebitdaratio 0.002 0.001 0 0.001 0.002 0.002 -0.021 -0.011 -0.005 -0.023 -0.03
operatingIncome -302 763 95 000 145 000 2M 2M 3M 4M -350M -80M -41M -22M -371M -81M -80M -642M -473M
operatingIncomeRatio -0.001 0 0 0.001 0.001 0.001 -0.022 -0.012 -0.006 -0.024 -0.026
totalOtherIncomeExpensesNet 99 617 -7M -7M -23M -6M -5M -6M -3M 117 000 -1M 2M -5M -6M -5M 21M 6M
incomeBeforeTax -203 146 -7M -7M -21M -3M -2M -3M -353M -83M -45M -19M -376M -86M -85M -621M -467M
incomeBeforeTaxRatio -0 -0.002 -0.002 -0.001 -0.001 -0.001 -0.023 -0.013 -0.005 -0.026 -0.028
incomeTaxExpense 0 3000 16 000 96 000 5000 37 000 51 000 251 000 102 000 14M 6M 0 12M 0 0 0
netIncome -2M -20M -18M -65M -17M -14M -14M -393M -93M -57M -25M -417M -98M -95M -670M -457M
netIncomeRatio -0.004 -0.006 -0.005 -0.005 -0.004 -0.004 -0.025 -0.016 -0.007 -0.029 -0.031
eps -0.2 -2.24 -2.04 -7.52 -0.2 -0.16 -0.16 -46.58 -1.1 -0.68 -0.3 -50.04 -1.18 -2.28 -80.76 -55.4
epsdiluted -0.2 -2.24 -2.04 -0.2 -0.16 -0.16 -1.1 -0.68 -0.3 -1.18 -2.28
weightedAverageShsOut 9M 9M 9M 9M 86M 86M 86M 8M 85M 84M 84M 8M 83M 83M 8M 8M
weightedAverageShsOutDil 9M 9M 9M 9M 86M 86M 86M 8M 85M 84M 84M 8M 83M 83M 8M 8M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-04-29 2024-05-14 2023-04-28 2022-04-29 2021-04-30
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -21M -11M -5M 4M -3M
ebit 8M -333M -363M -616M -473M
nonOperatingIncomeExcludingInterest -6M -17M -8M -27M 0
netIncomeFromContinuingOperations -21M -353M -376M -621M -467M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -65M -393M -417M -670M -457M
epsDiluted -7.52 -46.58 -50.04 -80.76 -55.4

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol YI YI YI YI YI YI YI YI YI YI YI YI YI YI YI YI
reportedCurrency CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-12-17 2025-09-17 2025-06-20 2024-11-27 2024-08-29 2024-03-21 2023-11-30 2023-06-15 2023-03-23 2022-09-30 2022-06-30
acceptedDate 2025-12-17 06:13:16 2025-09-17 06:09:10 2025-06-20 06:20:04 2025-04-29 06:05:37 2024-11-27 06:02:01 2024-08-29 06:04:08 2024-03-21 06:55:08 2024-05-14 08:49:42 2023-11-30 06:04:34 2023-06-15 06:47:39 2023-03-23 06:03:23 2023-04-28 06:18:03 2022-09-29 20:00:00 2022-06-29 20:00:00 2022-04-29 06:54:19 2021-04-30 06:05:03
calendarYear 2025 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 464M 447M 486M 462M 532M 495M 584M 604M 731M 576M 585M 674M 721M 666M 661M 1 190M
shortTermInvestments 30M 0 0 0 50M 100M 20M 50M 110M 123M 259M 206M 107M 205M 183M 300M
cashAndShortTermInvestments 494M 447M 486M 462M 582M 595M 604M 654M 841M 699M 844M 880M 827M 871M 844M 1 490M
netReceivables 358M 343M 361M 631M 506M 484M 535M 647M 656M 516M 481M 600M 496M 523M 495M 176M
inventory 1 254M 1 278M 1 343M 1 387M 1 532M 1 367M 1 433M 1 419M 1 481M 1 388M 1 468M 1 499M 1 241M 1 224M 1 121M 767M
otherCurrentAssets 282M 297M 295M 63M 267M 209M 213M 207M 180M 193M 226M 250M 227M 198M 332M 433M
totalCurrentAssets 2 388M 2 366M 2 485M 2 650M 2 887M 2 656M 2 786M 2 933M 3 195M 2 832M 3 020M 3 236M 2 792M 2 816M 2 802M 2 873M
propertyPlantEquipmentNet 81M 97M 107M 122M 124M 116M 122M 138M 147M 192M 194M 212M 237M 262M 314M 142M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6M
intangibleAssets 143 570 1M 1M 1M 0 2M 2M 2M 2M 3M 0 3M 0 0 5M 920 000
goodwillAndIntangibleAssets 143 570 1M 1M 1M 2M 2M 2M 2M 2M 3M 3M 3M 4M 4M 5M 7M
longTermInvestments 0 0 0 0 1 000 000 2M 2M 2M 2M 2M 2M 2M 2M 2M 3M 140 000
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 12M 12M 14M 15M 16M 13M 13M 13M 14M 21M 20M 20M 20M 21M 22M 5M
totalNonCurrentAssets 94M 110M 123M 138M 143M 133M 139M 156M 166M 218M 219M 238M 263M 288M 344M 154M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 2 482M 2 476M 2 608M 2 788M 3 030M 2 789M 2 925M 3 089M 3 361M 3 050M 3 239M 3 474M 3 055M 3 104M 3 146M 3 026M
accountPayables 1 550M 1 554M 1 680M 1 721M 1 912M 1 598M 1 642M 1 589M 1 815M 1 513M 1 681M 1 765M 1 548M 1 511M 1 347M 1 073M
shortTermDebt 170M 170M 149M 161M 169M 189M 207M 338M 349M 310M 270M 179M 230M 259M 260M 229M
taxPayables 0 0 0 4M 0 0 0 7M 0 0 0 38M 0 0 11M 10M
deferredRevenue 0 0 0 186M 0 0 0 193M 0 0 0 324M 0 0 203M 131M
otherCurrentLiabilities 506M 378M 346M 90M 569M 691M 736M 504M 817M 498M 550M 191M 481M 479M 69M 67M
totalCurrentLiabilities 2 227M 2 102M 2 175M 2 343M 2 650M 2 479M 2 584M 2 745M 2 981M 2 321M 2 501M 2 725M 2 258M 2 248M 2 130M 1 630M
longTermDebt 35M 43M 47M 0 64M 56M 55M 0 65M 89M 86M 0 115M 129M 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 2M 9M 9M 9M 8M 8M 6M 5M 0 0 0 0 -113 000 437 000 2M 4M
totalNonCurrentLiabilities 37M 52M 55M 64M 72M 64M 61M 68M 65M 89M 86M 100M 115M 129M 167M 66M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 35M 43M 47M 96M 64M 56M 55M 105M 65M 89M 86M 165M 115M 129M 231M 100M
totalLiabilities 2 264M 2 154M 2 230M 2 407M 2 722M 2 542M 2 645M 2 813M 3 046M 2 409M 2 587M 2 826M 2 373M 2 377M 2 297M 1 696M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 59 000 58 000 58 000 58 000 58 000 58 000 57 000 57 000 57 000 57 000 56 000 56 000 56 000 56 000 56 000 55 000
retainedEarnings -3 934M -3 921M -3 902M -3 884M -3 864M -3 847M -3 833M -3 819M -3 609M -3 516M -3 458M -3 427M -3 312M -3 215M -3 010M -2 340M
accumulatedOtherComprehensiveIncomeLoss 73M 73M 74M 74M 73M 74M 73M 73M 80M 82M 73M 76M 79M 69M 59M 63M
othertotalStockholdersEquity 3 177M 3 175M 3 171M 3 162M 3 157M 3 168M 3 015M 2 988M 2 962M 2 863M 2 831M
totalStockholdersEquity -684M -673M -656M -643M -630M -616M -591M -583M -513M -446M -423M -415M -371M -315M -173M 357M
totalEquity 219M 323M 378M 381M 308M 247M 279M 276M 315M 641M 652M 648M -371M -315M 849M 1 331M
totalLiabilitiesAndStockholdersEquity 2 482M 2 476M 2 608M 3 030M 2 789M 2 925M 3 361M 3 050M 3 239M 3 055M 2 062M
minorityInterest 903M 996M 1 034M 1 023M 937M 863M 871M 860M 829M 1 087M 1 075M 1 063M 1 052M 0 1 022M 973M
totalLiabilitiesAndTotalEquity 2 482M 2 476M 2 608M 2 788M 3 030M 2 789M 2 925M 3 089M 3 361M 3 050M 3 239M 3 474M 3 055M 2 062M 3 146M 3 026M
totalInvestments 30M 0 0 0 51M 102M 22M 52M 112M 125M 261M 208M 109M 207M 186M 300M
totalDebt 205M 213M 195M 257M 232M 246M 262M 443M 414M 398M 356M 344M 345M 388M 491M 329M
netDebt -259M -235M -291M -206M -299M -250M -323M -160M -317M -178M -229M -329M -376M -278M -170M -860M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-04-29 2024-05-14 2023-04-28 2022-04-29 2021-04-30
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 413M 647M 600M 495M 176M
otherReceivables 218M 0 0 0 0
prepaids 106M 6M 7M 9M 8M
totalPayables 1 807M 1 589M 1 887M 1 482M 1 073M
otherPayables 86M 0 122M 134M 0
accruedExpenses 58M 78M 80M 51M 91M
capitalLeaseObligationsCurrent 40M 43M 65M 66M 38M
capitalLeaseObligationsNonCurrent 55M 63M 100M 166M 62M
treasuryStock -6M -6M -41M -41M -35M
additionalPaidInCapital 3 173M 3 169M 2 977M 2 818M 2 669M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q2 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol YI YI YI YI YI YI YI YI YI YI YI YI YI YI YI
reportedCurrency CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-09-17 2025-06-20 2024-11-27 2024-08-29 2024-03-21 2023-11-30 2023-06-15 2023-03-23 2022-09-30 2022-06-30
acceptedDate 2025-09-17 06:09:10 2025-06-20 06:20:04 2025-04-29 06:05:37 2024-11-27 06:02:01 2024-08-29 06:04:08 2024-03-21 06:55:08 2024-05-14 08:49:42 2023-11-30 06:04:34 2023-06-15 06:47:39 2023-03-23 06:03:23 2023-04-28 06:18:03 2022-09-29 20:00:00 2022-06-29 20:00:00 2022-04-29 06:54:19 2021-04-30 06:05:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -20M -18M -21M 0 -14M -14M -353M -93M -57M 0 -376M -98M 0 -621M -457M
depreciationAndAmortization 0 0 17M 0 0 0 22M 0 0 0 41M 0 0 27M 14M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 0 86M -90M
stockBasedCompensation 3M 4M 20M 0 0 5M 227M 26M 24M 0 162M 0 0 146M 76M
changeInWorkingCapital 0 0 193M 0 0 0 -424M 0 0 0 44M 0 0 -370M 5M
accountsReceivables 0 0 122M 0 0 0 -50M 0 0 0 -87M 0 0 -242M -98M
inventory 0 0 28M 0 0 0 60M 0 0 0 -406M 0 0 -401M 24M
accountsPayables 0 0 133M 0 0 0 -177M 0 0 0 417M 0 0 274M 629M
otherWorkingCapital 0 0 -90M 0 0 0 -257M 0 0 0 120M 0 0 -924 000 -550M
otherNonCashItems -45M 126M 54M 110M 107M 122M 82M 102M 10M 0 106M 110M -30M 43M 335M
netCashProvidedByOperatingActivities -61M 113M 263M 110M 93M 108M -447M 35M -23M -121M -23M 12M -30M -689M -117M
investmentsInPropertyPlantAndEquipment 0 0 -15M 0 0 0 -10M 0 0 0 -32M 0 0 -63M -26M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 -3M 0 0 100 000 323M
purchasesOfInvestments 0 0 -460M 0 0 0 -914M 0 0 0 -1 269M 0 0 -1 835M -500M
salesMaturitiesOfInvestments 0 0 512M 0 0 0 1 074M 0 0 0 1 259M 0 0 1 958M 202M
otherInvestingActivites -223 000 -1M 50M -80M 30M 5M 19M 0 100M -52M
netCashUsedForInvestingActivites -223 000 -1M 50M -80M 30M 5M 19M -53M 100M -52M
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 0 0 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 -6M -12M
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 19M -73M -111M -104M -155M 110M 2M 0 -41M 6M
netCashUsedProvidedByFinancingActivities 19M -73M -111M -104M -155M 110M 2M 78M -41M 6M
effectOfForexChangesOnCash -774 000 -30 000 628 000 -313 000 -865 000 1M -4M 3M 329 000 -1M 4M 7M 7M -4M -8M
netChangeInCash -44M 39M -105M 49M -92M -16M -93M 153M -898 000 -98M -44M 79M -69M -558M 621M
cashAtEndOfPeriod 513M 557M 518M 564M 516M 607M 624M 766M 85M 619M 717M 759M 681M 761M 1 319M
cashAtBeginningOfPeriod 557M 518M 624M 516M 607M 624M 717M 613M 85M 717M 761M 681M 750M 1 319M 698M
operatingCashFlow -61M 113M 263M 110M 93M 108M -447M 35M -23M -121M -23M 12M -30M -689M -117M
capitalExpenditure 0 0 -15M 0 0 0 -10M 0 0 0 -32M 0 0 -63M -26M
freeCashFlow -61M 113M 248M 110M 93M 108M -457M 35M -23M -121M -55M 12M -30M -752M -142M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-04-29 2024-05-14 2023-04-28 2022-04-29 2021-04-30
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 458 000 2M -3M 216 000 -325M
netCashProvidedByInvestingActivities 37M 152M -47M 60M -325M
netDebtIssuance -177M 170M -81M 30M 134M
longTermNetDebtIssuance 0 0 0 42M 0
shortTermNetDebtIssuance -177M 170M -81M -12M 134M
netStockIssuance 14 000 223 000 274 000 -6M -6M
netCommonStockIssuance 14 000 223 000 274 000 -3M -6M
commonStockIssuance 14 000 223 000 274 000 3M 6M
netPreferredStockIssuance 0 0 0 -3M 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -229M 36M 103M 50M 942M
netCashProvidedByFinancingActivities -406M 206M 23M 74M 1 070M
incomeTaxesPaid 96 000 251 000 0 0 0
interestPaid 6M 10M 0 0 0

Earning call transcript

2024 q4
2025-03-20 ET (fiscal 2024 q4)
2024 q3
2024-11-27 ET (fiscal 2024 q3)
2024 q2
2024-08-29 ET (fiscal 2024 q2)
2024 q1
2024-05-23 ET (fiscal 2024 q1)
2023 q4
2024-03-21 ET (fiscal 2023 q4)
2023 q3
2023-11-30 ET (fiscal 2023 q3)
2023 q2
2023-08-24 ET (fiscal 2023 q2)
2023 q1
2023-06-15 ET (fiscal 2023 q1)
2022 q4
2023-03-24 ET (fiscal 2022 q4)
2022 q3
2022-12-01 ET (fiscal 2022 q3)
2022 q2
2022-08-25 ET (fiscal 2022 q2)
2022 q1
2022-06-16 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-06-04 ET
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
2026-04-09 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results
2025-12-17 ET
111, Inc. Announces Third Quarter 2025 Unaudited Financial Results
2025-09-17 ET
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results
2025-06-19 ET
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
2025-03-20 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
2025-03-12 ET
111, Inc. to Participate in Fireside Chat with Water Tower Research on March 26, 2025
2025-02-20 ET
111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow
2025-02-11 ET
111, Inc. Regains Compliance with NASDAQ Requirement
2025-01-08 ET
111, Inc. Announces ADS Ratio Change
2024-11-27 ET
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results
2024-11-21 ET
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024
2024-11-04 ET
111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow
2024-11-04 ET
111, Inc. Announces Change to Board of Directors
2024-10-22 ET
111, Inc. to Participate in Fireside Chat with Water Tower Research on October 30, 2024
2024-10-18 ET
111 to Announce Third Quarter 2024 Unaudited Financial Results on November 28, 2024 - Conference Call to Follow
2024-10-10 ET
111 Inc. Expands National Supply Chain Network with New Fulfillment Centers across South and Central China
2024-09-27 ET
111, Inc. Announces Receipt of Notification from Nasdaq
2024-09-13 ET
111 Inc. Announces Its Co-founders' Strategic Share Purchase and Highlights Continued Growth and Innovation
2024-08-27 12:00 ET
111, Inc. to Participate in Fireside Chat with Water Tower Research on September 5, 2024
2024-07-29 05:00 ET
111 to Announce Second Quarter 2024 Unaudited Financial Results on August 29, 2024 - Conference Call to Follow
2024-07-19 12:45 ET
111 Announces Appointment of New Auditor
2024-06-11 07:57 ET
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
2024-05-23 08:43 ET
111, Inc. Announces First Quarter 2024 Unaudited Financial Results
2024-04-30 06:30 ET
111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow
2024-03-21 08:47 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results
2024-03-01 09:00 ET
111 to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results- Conference Call to Follow
2024-02-27 13:58 ET
111 Announces Receipt of Withdrawal of Going Private Proposal
2023-11-30 06:00 ET
111, Inc. Announces Third Quarter 2023 Unaudited Financial Results
2023-11-13 05:10 ET
111 to Announce Third Quarter 2023 Unaudited Financial Results on November 30, 2023 - Conference Call to Follow
2023-08-24 06:00 ET
111, Inc. Announces Second Quarter 2023 Unaudited Financial Results
2023-07-31 09:59 ET
111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow
2023-06-15 05:22 ET
111, Inc. Announces First Quarter 2023 Unaudited Financial Results
2023-05-25 06:05 ET
111 to Announce First Quarter 2023 Unaudited Financial Results on June 15, 2023 - Conference Call to Follow
2023-03-23 06:17 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2022 Financial Results
2023-03-02 07:35 ET
111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow
2023-02-16 05:33 ET
111, Inc. Hosts Hua Medicine Launches First Official Flagship Store
2022-12-01 07:33 ET
111, Inc. Announces Third Quarter 2022 Unaudited Financial Results
2022-11-08 06:09 ET
111 to Announce Third Quarter 2022 Unaudited Financial Results on December 1, 2022 - Conference Call to Follow
2022-09-23 04:30 ET
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
2022-09-09 09:53 ET
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
2022-08-25 06:18 ET
111, Inc. Announces Second Quarter 2022 Unaudited Financial Results
2022-08-05 06:26 ET
111 to Announce Second Quarter 2022 Unaudited Financial Results on August 25, 2022 - Conference Call to Follow
2022-06-16 07:58 ET
111, Inc. Announces First Quarter 2022 Unaudited Financial Results
2022-05-26 08:59 ET
111 to Announce First Quarter 2022 Unaudited Financial Results on June 16, 2022 - Conference Call to Follow
2022-05-05 09:18 ET
111, Inc. Provides Updates on its Status Under the Holding Foreign Companies Accountable Act
2022-04-13 09:02 ET
111, Inc. Provides Urgently-needed Items and Online Services to Support Shanghai's Fight Against Covid-19 Pandemic
2022-03-17 07:20 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results
2022-03-14 11:35 ET
111, Inc. Becomes First Online Retail Platform for BGI's SARS-CoV-2 Virus Antigen Detection Kits
2022-03-04 09:24 ET
111, Inc. Reaches Strategic Partnership on Direct Supply with Beilin Pharmaceutical to Blaze New Trails in Digital Development of Chinese Patent Medicine
2022-02-22 08:38 ET
111 to Announce Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on March 17, 2022 - Conference Call to Follow
2021-11-19 05:31 ET
111, Inc. Announces Third Quarter 2021 Unaudited Financial Results
2021-10-28 23:00 ET
/C O R R E C T I O N -- 111, Inc./
2021-10-25 11:00 ET
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
2021-09-17 11:00 ET
111, Inc. Announces Participation in the Cantor Virtual Global Healthcare Conference
2021-09-07 09:00 ET
111, Inc. Announces $10 Million Share Repurchase Program
2021-09-07 ET
111, Inc. Announces $10 Million Share Repurchase Program
2021-08-27 06:30 ET
111, Inc. Announces Second Quarter 2021 Unaudited Financial Results
2021-08-16 12:00 ET
111, Inc. Deepens Partnership with Bayer Healthcare
2021-08-09 11:30 ET
111 to Announce Second Quarter 2021 Unaudited Financial Results on August 27, 2021 -Conference Call to Follow
2021-08-03 12:00 ET
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
2021-05-19 06:17 ET
111, Inc. Announces First Quarter 2021 Unaudited Financial Results
2021-04-21 12:00 ET
111 to Announce First Quarter 2021 Unaudited Financial Results on May 19, 2021 - Conference Call to Follow
2021-03-25 09:00 ET
111 Signs Strategic Cooperation Agreement with Jianming Pharmaceutical to Develop Chronic Disease Management Platform
2021-03-18 10:10 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results
2021-03-16 09:40 ET
111, Inc. Achieves Full Distribution Coverage Across Mainland China with the Opening of Two Key Fulfillment Centers
2021-02-25 11:00 ET
111 to Announce Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 18, 2021
2021-02-05 11:00 ET
111, Inc. Signs Strategic Cooperation Agreement with Jilin Baiyi Doctor Group to Create & Deliver New Models for Internet Medical Services
2020-12-22 09:22 ET
111, Inc. Announces Additional Round of New Capital Injection
2020-11-19 10:00 ET
111, Inc. Announces Third Quarter 2020 Unaudited Financial Results
2020-10-22 10:00 ET
111 to Announce Third Quarter 2020 Unaudited Financial Results on November 19, 2020
2020-10-19 10:50 ET
111, Inc. Teams Up with Bayer Healthcare to Explore the Vast Blue Ocean of Online Healthcare
2020-10-15 21:40 ET
111, Inc. Teams Up with Huluwa Pharmaceutical to Explore the New Domain of "Internet + pharmaceutical"
2020-10-15 21:35 ET
111 to be the Omni-channel Drug Commercialization Partner of Xiangxu Pharmaceutical for Traditional Chinese Medicine
2020-10-15 ET
111, Inc. and Shanghai Uniondrug Information Technology Join Hands to Advance Innovation in Commercial Insurance Payment
2020-09-30 ET
111, Inc. Builds Digitally-enabled, Omni-channel Drug Commercialization Platform as Part of its Goal to Provide Full Life-cycle Healthcare Management Solutions for Patients
2020-09-04 ET
111, Inc. Partners with Baiyunshan Pharmaceutical Sales in Digital Medicine Innovation
2020-08-20 ET
111, Inc. Announces Second Quarter 2020 Unaudited Financial Results
2020-08-20 ET
111, Inc. Announces New Capital Injection and Strategic Plan to Expand Access to China's Capital Markets
2020-07-31 ET
111 to Announce Second Quarter 2020 Unaudited Financial Results on August 20, 2020
2020-07-27 ET
111, Inc. Launched Lung Cancer Patient Care Program "Cloud Enabled Lung Cancer Care by Great Doctors" for Full Life-cycle Management of Tumor
2020-05-21 ET
111, Inc. Announces First Quarter 2020 Unaudited Financial Results
2020-05-08 ET
111 to Launch First Online Diabetes Patient Management Platform with Lilly China
2020-05-07 ET
111 to Announce First Quarter 2020 Unaudited Financial Results on May 21, 2020
2020-05-06 ET
Mr. Anfeng Guo, a Former BMS Oncology Business Unit Vice President Joins 111, Inc. as Chief Innovation Officer
2020-05-04 ET
111 Launched the Overseas Direct Delivery Service
2020-04-17 ET
111 Files Annual Report on Form 20-F for Fiscal Year Ended 2019
2020-03-27 ET
111 and Wenjiang People's Hospital to Build Online Cancer Diagnosis and Treatment Platform
2020-03-19 ET
111 Launches Free Consultation Services for Chinese Citizens Abroad against COVID-19
2020-03-12 ET
111, Inc. Announces Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results
2020-02-24 ET
Emergency Service from 111 Helps Companies Secure Epidemic Supplies to Open for Business
2020-02-20 ET
111 Partners with Financial Institutions in Battle Against Coronavirus
2020-02-20 ET
111 to Announce Fourth Quarter and Fiscal Year 2019 Unaudited Financial Results on March 12, 2020
2020-02-11 ET
111 Partners with Winhealth to Offer "Free Refill + End-to-End Delivery" Services to Patients with Chronic Diseases
2020-02-04 ET
111 Inc. Offers Free Online Consultation and Prescription Refill Services
2020-01-19 ET
111 Unveils New Video on The Impact of Chinese Policies to Medical Industry
2020-01-17 ET
111 Unveils New Video on the Impact of the Internet and other New Technologies on the Medical Industry
2020-01-17 ET
111, Inc. Featured at 38th Annual JP Morgan Healthcare Conference
2020-01-13 ET
111, Inc. Enters Into Strategic Partnership with Bestyoo to Upgrade Online Healthcare Service Model

SEC forms

Show financial reports only

SEC form 6
2026-06-04 10:54 ET
Yi Technology published news for 2026 q1
SEC form 6
2026-06-04 10:54 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 20
2026-04-30 10:04 ET
Yi Technology published news for 2026 q1
SEC form 6
2026-04-09 10:08 ET
Yi Technology published news for 2026 q1
SEC form 6
2026-04-09 10:08 ET
Yi Technology published news for 2026 q1
SEC form 6
2025-12-17 06:13 ET
Yi Technology published news for 2025 q3
SEC form 6
2025-12-17 06:13 ET
Yi Technology published news for 2025 q3
SEC form 6
2025-09-17 10:09 ET
Yi Technology published news for 2025 q2
SEC form 6
2025-09-17 10:09 ET
Yi Technology reported for 2025 q2
SEC form 6
2025-06-20 10:20 ET
Yi Technology published news for 2025 q1
SEC form 6
2025-06-20 10:20 ET
Yi Technology reported for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 20
2025-04-29 00:00 ET
Yi Technology published news for 2025 q1
SEC form 6
2025-03-20 07:26 ET
Yi Technology reported for 2024 q4
SEC form 6
2025-03-20 07:26 ET
Yi Technology published news for 2024 q4
SEC form 6
2025-02-11 13:05 ET
Yi Technology published news for 2024 q4
SEC form 6
2025-02-11 13:05 ET
Yi Technology published news for 2024 q4
SEC form 6
2024-11-27 06:02 ET
Yi Technology reported for 2024 q3
SEC form 6
2024-11-27 06:02 ET
Yi Technology published news for 2024 q3
SEC form 6
2024-11-04 06:19 ET
Yi Technology published news for 2024 q3
SEC form 6
2024-11-04 06:19 ET
Yi Technology published news for 2024 q3
SEC form 6
2024-08-29 06:04 ET
Yi Technology reported for 2024 q2
SEC form 6
2024-08-29 06:04 ET
Yi Technology published news for 2024 q2
SEC form 6
2024-07-19 06:08 ET
Yi Technology published news for 2024 q2
SEC form 6
2024-07-19 06:08 ET
Yi Technology published news for 2024 q2
SEC form 6
2024-05-23 06:05 ET
Yi Technology published news for 2024 q1
SEC form 6
2024-05-23 06:05 ET
Yi Technology reported for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 20
2024-05-14 00:00 ET
Yi Technology published news for 2024 q1
SEC form 6
2024-03-21 06:55 ET
Yi Technology reported for 2023 q4
SEC form 6
2024-03-21 06:55 ET
Yi Technology published news for 2023 q4
SEC form 6
2024-02-27 07:05 ET
Yi Technology published news for 2023 q4
SEC form 6
2024-02-27 07:05 ET
Yi Technology published news for 2023 q4
SEC form 6
2023-11-30 06:04 ET
Yi Technology reported for 2023 q3
SEC form 6
2023-08-24 06:10 ET
Yi Technology reported for 2023 q2
SEC form 6
2023-06-15 06:47 ET
Yi Technology reported for 2023 q1
SEC form 6
2023-04-28 06:18 ET
Yi Technology published news for 2023 q1
SEC form 20
2023-04-28 00:00 ET
Yi Technology published news for 2023 q1
SEC form 6
2023-03-23 06:03 ET
Yi Technology published news for 2022 q4
SEC form 6
2022-12-01 06:09 ET
Yi Technology published news for 2022 q3
SEC form 6
2022-09-23 06:05 ET
Yi Technology published news for 2022 q2
SEC form 6
2022-09-09 06:13 ET
Yi Technology published news for 2022 q2
SEC form 6
2022-08-25 06:04 ET
Yi Technology published news for 2022 q2
SEC form 6
2022-06-16 06:02 ET
Yi Technology published news for 2022 q1
SEC form 6
2022-05-05 07:56 ET
Yi Technology published news for 2022 q1
SEC form 6
2022-04-29 06:54 ET
Yi Technology published news for 2022 q1
SEC form 20
2022-04-29 00:00 ET
Yi Technology published news for 2022 q1
SEC form 6
2022-03-17 06:49 ET
Yi Technology published news for 2021 q4
SEC form 6
2022-03-01 06:16 ET
Yi Technology published news for 2021 q4
SEC form 6
2021-11-19 06:02 ET
Yi Technology published news for 2021 q3
SEC form 6
2021-09-07 06:36 ET
Yi Technology published news for 2021 q2
SEC form 6
2021-08-27 06:02 ET
Yi Technology published news for 2021 q2
SEC form 6
2021-05-19 07:39 ET
Yi Technology published news for 2021 q1
SEC form 6
2021-04-30 06:05 ET
Yi Technology published news for 2021 q1
SEC form 20
2021-04-30 00:00 ET
Yi Technology published news for 2021 q1
SEC form 6
2021-03-18 08:34 ET
Yi Technology published news for 2020 q4
SEC form 6
2020-12-22 06:06 ET
Yi Technology published news for 2020 q3
SEC form 6
2020-11-19 06:31 ET
Yi Technology published news for 2020 q3
SEC form 6
2020-11-06 06:01 ET
Yi Technology published news for 2020 q3